Loss of muscle mass in the end of life in patients with advanced cancer

Muscle mass depletion is associated with adverse outcomes in cancer patients. There is limited information on the impact of age, sex, tumor type, and inflammation on muscle loss in the end of life of cancer patients. Muscle depletion and loss of muscle in the last 2 years of life was estimated in 471 cancer patients from 779 dual-energy X-ray absorptiometry scans. A linear mixed model was used to estimate the impact of age, sex, tumor type, and inflammation. Patients above median age (> 71 years) had less muscle mass (-1.1 +/- 0.3 kg, P < 0.001). Prevalence of muscle depletion was higher in men than women (59 vs. 28 %, P < 0.001). Men lost muscle mass over time (mean, 1.4 +/- 0.3 kg/year, P < 0.001) contrary to women (0.3 +/- 0.4 kg/year, P = 0.5). Patients with pancreatic cancer had less muscle mass than patients with biliary tract and colorectal cancers (P < 0.02). There were no differences in muscle loss over time in patients grouped by median age or tumor type. The prevalence of elevated C-reactive protein was 61 to 70 % during the study. Patients with C-reactive protein > 10 mg/L had less muscle mass (0.6 +/- 0.2 kg, P < 0.001) and lost muscle mass at an accelerated pace during the disease trajectory (0.7 +/- 0.3 kg/year, P = 0.03). Muscle loss in advanced cancer is related to age, sex, tumor type, and inflammation. The mechanism(s) behind the apparent sexual dimorphism warrants further study.